Get the app!
Back to Trades
Buy4

Artiva Biotherapeutics, Inc.

ARTV

Total Value
$16.5M
Net $16.5M bought
Purchases
$16.5M
2 transactions

Company Information

Ticker Symbol
ARTV
CIK
0001817241

Insider Information

Role
Insider

Filing Details

Filing Date
May 28, 2026
Transaction Date
May 11, 2026
Accession Number
0001931382-26-000007
Form Type
4
Net Trading Amount
$16.5M

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
May 11, 2026Common Stock1,085,069$11.52Purchase$12.5M
May 11, 2026Common Stock347,222$11.52Purchase$4.0M

Footnotes

  1. (F1)GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by GC Corp., except to the extent of any pecuniary interest therein.
  2. (F2)The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.